Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 104.00K | 41.00K | 243.00K | 120.00K | 121.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.00K | 41.00K | 243.00K | 120.00K | 121.00K |
| Cost of Revenue | -- | -- | 5.08M | 8.20M | -- |
| Gross Profit | 104.00K | 41.00K | -4.83M | -8.08M | 121.00K |
| SG&A Expenses | 3.80M | 6.13M | 3.00M | 3.90M | 3.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.72M | 12.89M | 8.07M | 12.09M | 14.90M |
| Operating Income | -9.62M | -12.85M | -7.83M | -11.97M | -14.78M |
| Income Before Tax | -9.23M | -12.35M | -7.22M | -11.26M | -13.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.23M | -12.35M | -7.22M | -11.26M | -13.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.23M | -12.35M | -7.22M | -11.26M | -13.94M |
| EBIT | -9.62M | -12.85M | -7.83M | -11.97M | -14.78M |
| EBITDA | -9.53M | -12.76M | -7.74M | -11.89M | -14.68M |
| EPS Basic | -0.14 | -0.18 | -0.11 | -0.17 | -0.21 |
| Normalized Basic EPS | -0.08 | -0.11 | -0.07 | -0.11 | -0.13 |
| EPS Diluted | -0.14 | -0.18 | -0.11 | -0.17 | -0.21 |
| Normalized Diluted EPS | -0.08 | -0.11 | -0.07 | -0.11 | -0.13 |
| Average Basic Shares Outstanding | 68.40M | 68.35M | 67.43M | 66.88M | 66.53M |
| Average Diluted Shares Outstanding | 68.40M | 68.35M | 67.43M | 66.88M | 66.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |